Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Dianthus Therapeutics

Biotech & Life Sciences · New York City, United States · Founded 2019 · IPO 2023 Unicorn

Biotech company developer of therapeutics and drugs

Valuation
$4.38B
Market cap · May/2026
Revenue
$2.0M
Latest reported FY
Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

19 investors on Dianthus Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 7 investors entered at this stage
Tellus BioVentures
Wedbush Morgan Securities
5AM Ventures
Avidity Partners
Venrock Healthcare Capital Partners
Fairmount Funds Management
Fidelity Investments
Series B+ 12 investors entered at this stage
Logos Capital
Octagon Capital Advisors
RA Capital Management
StemPoint Capital
Great Point Partners
Woodline Partners
Bain Capital Life Sciences
Ally Bridge Group
Vestal Point Capital
Catalio Capital Management
RTW Investments
Logos Capital Group

Global footprint

Where Dianthus Therapeutics has talent and traffic

Workforce by country
🇺🇸 United States · New York City HQ
Book a demo for the full country breakdown
Web traffic by country
11K monthly visits
across markets
🇺🇸 United States75.5%
🇮🇳 India20%
🇫🇷 France4.5%
Top 3 markets shown

Market sentiment

What the market is saying about Dianthus Therapeutics

An AI-synthesized read of the highest-engagement posts about Dianthus Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Dianthus Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles